The genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data

BACKGROUND: Neoadjuvant chemotherapy (NACT) becomes the first-line option for advanced tumors, while patients who are not sensitive to it may not benefit. Therefore, it is important to screen patients suitable for NACT. METHODS: Single-cell data of lung adenocarcinoma (LUAD) and esophageal squamous...

Descripción completa

Detalles Bibliográficos
Autores principales: Sui, Qihai, Hu, Zhengyang, Jin, Xing, Bian, Yunyi, Liang, Jiaqi, Zhang, Huan, Yang, Huiqiang, Lin, Zongwu, Wang, Qun, Zhan, Cheng, Chen, Zhencong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249226/
https://www.ncbi.nlm.nih.gov/pubmed/37291676
http://dx.doi.org/10.1186/s13578-023-01061-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249226/
https://www.ncbi.nlm.nih.gov/pubmed/37291676
http://dx.doi.org/10.1186/s13578-023-01061-z

Ejemplares similares